PILA PHARMA AB

PILA PHARMA AB has revised the operational plan for its upcoming clinical trial, PP-CT03, a phase 2a trial focusing on safety and tolerability in individuals with obesity and type 2 diabetes. Initially set to be conducted at a non-hospital site using digital approaches, concerns about handling safety events have led to the decision to conduct the trial at a hospital site instead. This change is expected to slightly delay the clinical trial application submission but will allow for better management of higher doses and potential safety issues. The trial aims to establish the maximal tolerable dose of XEN-D0501 and assess its efficacy in weight reduction. The company is evaluating the impact on costs and timelines. PILA PHARMA is a Swedish biotech company focusing on developing TRPV1 antagonists for type 2 diabetes and other inflammatory diseases. The company owns several patents and is involved in projects related to diabetes, erythromelalgia, and abdominal aorta aneurism.

Pila Pharma AB (publ) (FN STO: PILA) announced that CEO Gustav H. Gram has purchased an additional 29,375 shares at an average price of SEK 5.1768, increasing his total holdings to 74,816 shares. Gram expressed his commitment to the company and confidence in its progress, citing an upcoming value-driving trial. Pila Pharma is focused on developing TRPV1 antagonists, particularly XEN-D0501, for type 2 diabetes, obesity, and cardiovascular diseases. The company has completed two phase 2a clinical trials showing good tolerability and efficacy in type 2 diabetic patients. Pila Pharma also has projects targeting erythromelalgia and abdominal aorta aneurism. The company's shares are traded on Nasdaq First North Growth Market, Sweden.

PILA PHARMA AB (publ) invites investors to participate in three upcoming online events where CEO Gustav H. Gram will discuss the company's Half-year report for 2024 and answer questions about their innovative pill treatment for obesity and diabetes. The events are scheduled as follows: 1. Stokk.io Online Webinar on Tuesday, August 27, 2024, at 12:00 CET 2. Aktiespararna Online Life Science Day on Wednesday, August 28, 2024, at 20:00 CET 3. Redeye Online Investor Event on Thursday, August 29, 2024, at 14:00 CET PILA PHARMA is a Swedish biotech company focused on developing TRPV1 antagonists for treating type 2 diabetes and other inflammatory diseases. Their lead candidate, XEN-D0501, has shown promise in clinical trials and has received orphan drug designation for erythromelalgia. The company is preparing for further trials to assess the safety and efficacy of XEN-D0501 in obese patients with type 2 diabetes. For more information and to sign up for the events, visit the provided links or the company's website. PILA PHARMA's share ticker PILA is traded on the Nasdaq First North Growth Market in Sweden.

Pila Pharma AB's Board of Directors, authorized by a general meeting, has decided to issue 3,333,334 new shares at SEK 3.00 per share, raising approximately SEK 10 million before transaction costs. The new shares, allocated to subscribers based on payment, will increase the share capital by SEK 142,520.48683 and dilute existing capital and voting rights by 12.29%. The offer targeted a limited number of current and new investors, with 19 identified contacts, resulting in 15 individual presubscriptions. The company aims to use the funds for a phase 2a clinical study of its TRPV1 antagonist, XEN-D0501, to assess its effect on body weight regulation in obese, diabetic patients. The legal advisor for the issue is MAQS Advokatbyrå, and the issuing agent is Nordic Issuing AB. The information is published in compliance with the EU Market Abuse Regulation. Pila Pharma, listed on Nasdaq First North Growth Market, focuses on developing treatments for type 2 diabetes, erythromelalgia, and abdominal aorta aneurism using TRPV1 antagonists.

PILA PHARMA AB has announced an agreement with UK-based clinical research organization Lindus Health to support the submission of a clinical trial application for PP-CT03, a phase 2a study targeting obese individuals with type-2 diabetes. Lindus Health, known for its expertise in metabolic health and technology-driven trial execution, will assist in compiling and submitting the application. The trial aims to determine the maximum tolerable dose of XEN-D0501, assess its safety and tolerability, and evaluate its effects on body weight over three months. Recruitment is expected to begin in early autumn, pending approval. CEO Gustav H. Gram expressed optimism about the collaboration, highlighting Lindus Health's innovative model. PILA PHARMA focuses on developing TRPV1 antagonists for type 2 diabetes and other inflammatory diseases, with XEN-D0501 as a key candidate. The company also works on projects related to erythromelalgia and abdominal aorta aneurism. Lindus Health specializes in running efficient clinical trials and has conducted over 90 studies across various conditions.

The Board of Directors of Pila Pharma AB has decided to issue up to 3,333,334 new shares at a subscription price of SEK 3.00 per share, potentially raising approximately SEK 10.0 million before transaction costs. This decision, authorized by a general meeting on April 18, 2024, deviates from shareholders' preferential rights and targets a limited number of current shareholders and new investors. The subscription period ends on July 23, 2024, but may be extended by the board. The funds will support the company's expansion and a clinical trial application, necessitated by recent trial design changes to include more participants. The transaction could cause a dilution effect of approximately 12.29% for non-participating shareholders. The subscription price was set based on a 30% discount on the Volume-Weighted Average Price (VWAP) from June 17 to July 5, 2024. The company aims to demonstrate sufficient funds for an ethics committee to approve the clinical trial, which could potentially enhance shareholder value. The legal advisor for the transaction is MAQS Advokatbyrå, and Nordic Issuing AB will act as the issuing agent.

PILA PHARMA announced its participation and co-sponsorship of the 41st International Symposium on Diabetes and Nutrition in Uppsala, Sweden from June 27-30. The company aims to spread awareness about using TRPV-1 antagonists for treating diabetes and other metabolic conditions. Dr. Dorte X. Gram, CSO and Founder, will present on targeting the TRPV1 receptor. PILA PHARMA is a Swedish biotech company focusing on developing TRPV1 antagonists, particularly XEN-D0501, for type 2 diabetes, obesity, and other conditions. They have completed two phase 2a trials showing XEN-D0501's safety and efficacy. The company is preparing for further clinical trials to determine the maximal tolerable dose in overweight or obese individuals with type 2 diabetes. PILA PHARMA also focuses on erythromelalgia and abdominal aorta aneurism research.

The conference in Uppsala, Sweden, from June 27-30, will feature PILA PHARMA, invited by Professor Ulf Risérus of Uppsala University, a prominent expert in diabetes, nutrition, and obesity science. The event will gather international experts on these topics, with PILA PHARMA sponsoring SEK 50,000. Dr. Dorte X. Gram, CSO and Founder of PILA PHARMA, will present on using TRPV-1 antagonists to treat diabetes and other metabolic conditions. PILA PHARMA, based in Malmö, Sweden, focuses on developing TRPV1 antagonists as treatments for type 2 diabetes and other inflammatory diseases. They own the development candidate XEN-D0501, which has shown promise in clinical trials for diabetes and other conditions. The company also holds patents and aims to submit further patents related to TRPV1 antagonists. XEN-D0501 is a synthetic TRPV1 antagonist with applications in pain and inflammatory diseases, including diabetes. It has demonstrated good safety and efficacy in clinical trials, with plans for further studies to identify the maximum tolerable dose in overweight or obese type 2 diabetes patients. Diabetes and obesity are global health challenges, with significant unmet needs in treatment. Obesity often precedes type 2 diabetes and increases the risk of cardiovascular diseases. Advances in anti-obesity drugs have shown benefits in quality of life and longevity. Erythromelalgia is a rare disease causing pain and redness in extremities, with PILA PHARMA planning a proof-of-concept study on XEN-D0501's effects on this condition. Abdominal Aorta Aneurism is a cardiovascular disease with no current preventive treatments. PILA PHARMA is collaborating on research to investigate XEN-D0501's impact on the condition's growth in mice.

PILA PHARMA AB (publ) (FN STO: PILA) will present at the Aktiespararna's "Store Aktiedagarna" event on Wednesday, June 12, 2024, at 08:00 CET. The presentation will take place in Stockholm, Sweden, and will be livestreamed. CEO Gustav H. Gram will discuss the company's latest developments and its innovative oral treatment for diabetes. The event will be in English and include a Q&A session. Pila Pharma is a Swedish biotech company focused on developing TRPV1 antagonists for type 2 diabetes and other inflammatory diseases. The company owns the development candidate XEN-D0501 and has completed two phase 2a clinical trials showing it is well tolerated by type 2 diabetic patients. Pila Pharma aims to further study XEN-D0501's effects on diabetes, obesity, erythromelalgia, and abdominal aorta aneurism. For more information, contact CEO Gustav H. Gram at ghg@pilapharma.com or visit the company's website. Pila Pharma's shares trade on Nasdaq First North Growth Market, Sweden.

PILA PHARMA AB kommer att presentera på Redeye Theme: Diabetes idag, torsdag 23 maj 2024 kl 09:30 CEST. Presentationen kommer att hållas i Redeye's studio i Stockholm och kommer även att livestreamas. Intresserade parter och investerare är inbjudna att följa evenemanget och ställa frågor. VD Gustav H. Gram kommer att diskutera PILA Pharmas position inom diabetesområdet och hur deras innovativa orala behandling kan spela en roll i framtida behandling av diabetes och dess associerade sjukdomar. Det kommer även att vara en frågestund där frågor från Redeye-analytiker Filip Einarsson kommer att besvaras. PILA PHARMA är ett svenskt biotechföretag baserat i Malmö. Företaget äger en TRPV1-tillgång med data och kemiska enheter, inklusive utvecklingskandidaten XEN-D0501. De äger också användningspatent som täcker användningen av TRPV1-antagonister som behandling av fetma och diabetes och avser att lämna in ytterligare patent. Företagets aktier, PILA, handlas på Nasdaq First North Growth Market, Sverige. XEN-D0501 är en selektiv, syntetisk potent liten molekyl TRPV1-antagonist som licensierades in 2016. PILA Pharma har hittills slutfört två fas 2a kliniska prövningar (PP-CT01 och PP-CT02) som båda visade att XEN-D0501 tolereras väl av typ 2-diabetespatienter. Dessutom visade PP-CT02 att XEN-D0501 förbättrade den endogena insulinresponsen till oral glukos. Diabetes är en global pandemi med en förbluffande uppskattad förekomst av mer än 537 miljoner människor som lever med diabetes, motsvarande cirka 8-10% av den globala vuxna befolkningen. Trots nyligen terapeutiska framsteg finns det stora och växande ouppfyllda behov både från effektivitet, säkerhet och tillgänglighet.